Considering GLP-1 agonists’ observed potential mechanisms of action as indirect anti-estrogenic and direct anti-inflammatory therapy, it is possible to consider them for future use as an alternative treatment in cases of severe or refractory dysmenorrhea. The gene discussed is GCG; the disease is Dysmenorrhea.